Bengaluru: Morphle Labs, the Bengaluru-based deep-tech healthcare automation company building next-generation robotic and imaging systems for cancer diagnostics, has raised USD 5 million in a Series A round, by Inflexor Ventures. The funding will enable the company to accelerate global market expansion, scale manufacturing for its flagship products RoboTome® and MorphoLens, invest in global regulatory approvals, and deepen its technology and IP leadership as it expands into major international markets.
Founded in 2017, Morphle Labs is addressing one of the most underserved but critical aspects of healthcare: automation in histopathology, the core of cancer diagnostics. While radiology and hematology have rapidly digitised/automated, anatomic pathology continues to rely on manual, labour-intensive processes that have barely changed in decades. Globally, histopathology labs are struggling with acute talent shortages, with over 60% reporting unfilled positions leading to rising case backlogs and delays that impact patient care. Morphle is rebuilding these workflows from first principles by integrating robotics, precision hardware, optics, and computer vision.
The company’s flagship platform, RoboTome®, is the first robotic microtome of its kind, capable of slicing biopsy blocks at over twice the speed of an experienced histotechnologist while delivering unmatched consistency in section quality, a critical requirement for downstream diagnostics. Its complementary platform, MorphoLens, is a high-throughput slide scanner that digitises 100+ slides per hour through robust optics and AI-driven imaging, enabling remote pathology and scalable diagnostic operations. Together, the platforms automate some of the most complex and historically manual steps in histology, forming an end-to-end workflow that improves speed, reliability, and clinical readiness. Morphle has filed 80+ patents across robotics, optics, embedded systems, and imaging, underscoring its deep R&D culture.
Commenting on the fundraise, Rohit Hiwale, Founder & CEO, Morphle Labs, said, “Our vision at Morphle is to rethink healthcare from the ground up. Histology remains one of the few critical domains still untouched by true automation, and that is where we have chosen to start. With RoboTome® and MorphoLens, we have tackled two of the most challenging bottlenecks in diagnostics, high-throughput robotic microtomy and robust, modular slide imaging, but this is only the beginning. The larger opportunity lies in stitching together every broken link in the diagnostics chain, enabling labs to deliver faster, higher-quality results and empowering pathologists to focus on what matters most: the diagnosis.”
With this funding we will also be expanding our team, While solving some extremely valuable problems for mankind, we are on a mission to improve talent density across Robotics & computer vision.
The company is led by a deeply technical founding team: Rohit Hiwale, Chief Executive Officer (CEO), an IIT Kharagpur alumnus and second-time founder with engineering experience at Walmart Labs and Rippling; Ashish Manmode, Chief Technology Officer (CTO), an IIT Kharagpur alumnus specialising in systems integration and full-stack robotics; and Sunnel Daniel, Chief Operating Officer (COO), who leads business, regulatory, and customer operations and has been instrumental in driving early commercial adoption. Their combined expertise spans robotics, optics, computer vision, precision systems, compliance, and customer-centric product design. Morphle’s 100-member team is based primarily in Bengaluru and Boston, with an expanding commercial presence in the U.S. and Europe.
Speaking about the investment, Pratip Mazumdar, Partner at Inflexor Ventures, said, “Morphle Labs is transforming one of the most overlooked yet mission-critical segments of global healthcare. Their ability to bring together robotics, imaging, and AI into clinically reliable systems is exceptional. The traction they are already seeing with leading labs in the U.S. and Europe demonstrates both the scale of the problem and Morphle’s ability to solve it. We believe they are poised to become a global leader in tissue diagnostics automation, and we are excited to support their journey.”
With the newly secured funding, Morphle Labs will scale manufacturing to meet accelerating global demand for RoboTome® and MorphoLens, expand its IP portfolio across international jurisdictions, and push forward on global regulatory certifications essential for medical device commercialisation. The company also plans to grow its engineering, research, and product teams across robotics, vision systems, optics, hardware development, medical-grade software, and compliance. The company is significantly scaling its team to accelerate its roadmap in physical AI—the convergence of intelligent software with high fidelity hardware. The company is hiring across all levels, from senior technical talent to early-career builders, to help shape the future of AI-driven physical systems.
Beyond its current platforms, Morphle is building integrated automation layers across the tissue diagnostics workflow, creating a seamless, AI and robotics-powered pipeline that could significantly reduce diagnostic turnaround times and improve outcomes for cancer patients worldwide.
Morphle Labs is pioneering the future of “physical AI” in diagnostics, showing how world-class medical innovation can be built in India. The company is now positioned to redefine the way tissue diagnostics is performed from tissue to digital interpretation.
